MLYS Mineralys Therapeutics, Inc.

NASDAQ
$25.86

Mineralys Therapeutics, Inc. (MLYS) is expected to report earnings on November 10, 2026, after the market close. The consensus earnings estimate is a loss of $0.53 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +3.0% since its last earnings release on August 11, 2026.

Mineralys Therapeutics Missed Consensus Estimates
Tuesday, August 11, 2026 · 4:05 PM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 10
Tuesday · 4:05 PM ET
Earnings Whisper
-
vs ($0.53)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $27.77

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Mineralys Therapeutics, Inc.

Mineralys is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone.

Sector

Healthcare

Industry

Biotechnology

Held By 1 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.